Jelena Bila

Prof. Dr. Jelena Bila

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
Jelena BilaJelena Bila
Jelena Bila
ASAleksandra Sretenovic
Aleksandra Sretenovic
JJJelena Jelicic
Jelena Jelicic
NTNatasa Tosic
Natasa Tosic
IGIrena Glumac
Irena Glumac
BMBiljana Mihaljevic
Biljana Mihaljevic

31 August 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Jelena BilaJelena Bila
Jelena Bila
Eirini KatodritouEirini Katodritou
Eirini Katodritou
MGMargarita Guenova
Margarita Guenova
SBSandra Bašić-Kinda
Sandra Bašić-Kinda
DCDaniel Coriu
Daniel Coriu
Meletios-Athanasios DimopoulosMeletios-Athanasios Dimopoulos
Meletios-Athanasios Dimopoulos
The course of multiple myeloma (MM) is influenced by a variety of factors, including the specificity of the tumour microenvironment (TME). The aim of this review is to provide insight into the interplay of treatment modalities used in the current clinical practice and TME. Bortezomib-based triplets are the standard for MM first-line treatment. Bortezomib is a proteasome inhibitor (PI) which inhibits the nuclear factor kappa B (NF-κB) pathway. However, bortezomib is decreasing the expression of chemokine receptor CXCR4 as well, possibly leading to the escape of extramedullary disease. Immunomodulatory drugs (IMiDs), lenalidomide, and pomalidomide downregulate regulatory T cells (Tregs). Daratumumab, anti-cluster of differentiation 38 (anti-CD38) monoclonal antibody (MoAb), downregulates Tregs CD38+. Bisphosphonates inhibit osteoclasts and angiogenesis. Sustained suppression of bone resorption characterises the activity of MoAb denosumab. The plerixafor, used in the process of stem cell mobilisation and harvesting, block the interaction of chemokine receptors CXCR4-CXCL12, leading to disruption of MM cells’ interaction with the TME, and mobilisation into the circulation. The introduction of several T-cell-based immunotherapeutic modalities, such as chimeric-antigen-receptor-transduced T cells (CAR T cells) and bispecific antibodies, represents a new perspective in MM treatment affecting TME immune evasion. The optimal treatment approach to MM patients should be adjusted to all aspects of the individual profile including the TME niche.

19 September 2017 in Oncology Research and Treatment
Verified
Journal Article
Closed access
PDF file
Jelena BilaJelena Bila
Jelena Bila
JJJelena Jelicic
Jelena Jelicic
MFMarija Dencic Fekete
Marija Dencic Fekete
GTGoran Trajkovic
Goran Trajkovic
ASAleksandra Sretenovic
Aleksandra Sretenovic
BMBiljana Mihaljevic
Biljana Mihaljevic
Background: The Revised International Staging System (R-ISS) has recently been introduced as a comprehensive prognostic score for multiple myeloma (MM). Validation of the R-ISS in patients treated outside of clinical trials is the focus of current investigations. The aim of this study was to test the prognostic role of the R-ISS in MM patients ineligible for autologous stem cell transplantation. Patients and Methods: A total of 102 newly diagnosed MM patients were analyzed. All patients were initially treated with thalidomide-based combinations. Results: An overall response rate was achieved in 77.4% patients. Both the International Staging System (ISS) and the R-ISS influenced the event-free survival and the overall survival (OS). However, the ISS was unable to discriminate patients in stages ISS1 and ISS2 regarding OS. On the contrary, the R-ISS clearly differentiated risk categories regarding OS and provided an improved discriminative power of 6.3% compared to the ISS. Furthermore, among the parameters that were significant in univariate analysis (presence of renal impairment, anemia, platelet count < 130 × 109/l, and R-ISS), the multivariate model pointed to the R-ISS (p = 0.001) as the most important parameter influencing OS. Conclusion: The R-ISS represents a useful tool for risk stratification of transplant-ineligible MM patients and should be considered as a prognostic index in daily clinical practice.

16 September 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
KGKristin Gerhardt
Kristin Gerhardt
MJMadlen Jentzsch
Madlen Jentzsch
TGThomas Georgi
Thomas Georgi
ASAleksandra Sretenović
Aleksandra Sretenović
MCMichael Cross
Michael Cross
VVVladan Vucinic
Vladan Vucinic
Up to 60% of patients with aggressive B-cell lymphoma who receive chimeric antigen receptor (CAR) T-cell therapy experience treatment failure and subsequently have a poor prognosis. Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains a potentially curative approach for patients in this situation. Induction of a deep response prior to alloHSCT is crucial for long-term outcomes, but the optimal bridging strategy following relapse after CAR T-cell therapy has not yet been established. Polatuzumab vedotin, an antibody drug conjugate targeting CD79b, is a novel treatment option for use in combination with rituximab and bendamustine (Pola-BR) in relapsed or refractory disease. Patients: We report two heavily pretreated patients with primary refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma (PMBCL) respectively who relapsed after therapy with CAR T-cells with both nodal and extranodal manifestations of the disease. After application of three courses of Pola-BR both patients achieved a complete metabolic remission. Both patients underwent alloHSCT from a human leukocyte antigen (HLA)-mismatched donor following conditioning with busulfan and fludarabine and are disease free 362 days and 195 days after alloHSCT respectively. We conclude that Pola-BR can be an effective bridging therapy before alloHSCT of patients relapsing after CAR T-cell therapy. Further studies will be necessary to define the depth and durability of remission of this salvage regimen before alloHSCT.

23 August 2024 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
EKEfstathios Kastritis
Efstathios Kastritis
MBMeral Beksac
Meral Beksac
SBSorina Nicoleta Badelita
Sorina Nicoleta Badelita
EKEirini Katodritou
Eirini Katodritou
Jelena BilaJelena Bila
Jelena Bila
Meletios-Athanasios DimopoulosMeletios-Athanasios Dimopoulos
Meletios-Athanasios Dimopoulos

17 December 2024 in Cancers
Verified
Journal Article
Open access
PDF file
NSNikica Sabljic
Nikica Sabljic
Nikola PanticNikola Pantic
Nikola Pantic
MVMarijana Virijevic
Marijana Virijevic
JRJovan Zoran Rajic
Jovan Zoran Rajic
MČMirjana Čučaković
Mirjana Čučaković
MMMirjana Mitrovic
Mirjana Mitrovic
Background: Acute promyelocytic leukemia (APL) is frequently associated with disseminated intravascular coagulation (DIC), leading to potentially life-threatening bleeding. Compared to bleeding, thromboses are a less commonly encountered problem. Objective: The objective of our study was to identify the incidence and predictive value of demographic data, clinical–laboratory parameters, and thrombosis risk assessment models (RAMs) for venous thromboembolism (VTE) in patients with APL. Methods: This study was a retrospective study conducted on adult patients with APL who were treated between 2006 and 2024 at the Clinic of Hematology UCCS with all-trans retinoic acid (ATRA) and anthracycline. The demographic and clinical–laboratory data related to VTE were collected and analyzed alongside the predictive value of two RAMs proposed by Al-Ani and Paterno and colleagues. Results: Among the one-hundred-fifty-five adult patients with APL, VTE was diagnosed in twenty-eight cases (18.1%). The most common location for thrombosis was in the central venous catheter (CVC), which affected twelve (42.8%) patients. A total of six (21.4%) patients had deep vein thrombosis (DVT), one patient (3.6%) showed a pulmonary embolism (PE), and thrombosis at unusual sites was present in nine (32.1%) patients. Our analyses showed that neither Al-Ani’s RAM nor the RAM proposed by Paterno and colleagues were predictive for VTE in patients with APL. The C statistics value for the Al-Ani model was ROC = 0.514, and, for Paterno’s RAM, it was ROC = 0.521. The independent risk factors for VTE, identified via multivariate analysis, were CD114 expression (p = 0.005, OR = 6.4 IC 95%: [1.8–23.2]) and the absence of bleeding at presentation (p = 0.013, OR = 0.086 IC 95%: [0.01–0.59]). Conclusions: To the best of our knowledge, this is the first study showing that a higher expression of CD114 increases the risk of VTE. The absence of bleeding at presentation in patients with APL correlates with thrombosis. Further analyses are needed to confirm these findings and help to develop therapeutic strategies to prevent VTE complications. So far, no risk assessment model has been sufficient to stratify patients with APL according to their risk of VTE.